Regulations.gov document
Comment from Fidelis Pharmaceuticals, Inc.
Other · FDA-2017-D-2462 · posted Sep 8, 2021
Key facts
| Document ID | FDA-2017-D-2462-0057 |
|---|---|
| Title | Comment from Fidelis Pharmaceuticals, Inc. |
| Document type | Other |
| Subtype | Guidance |
| Agency | FDA |
| Docket | FDA-2017-D-2462 |
| Posted | Sep 8, 2021 |
| Comment period opens | Jan 24, 2022 |
At a glance
- 10–99 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: